Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Japanese and Chinese Male Subjects (Randomized, Double-blind, Placebo-controlled Design Within Dose Groups)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Apr 2019
Price :
$35
*
At a glance
- Drugs Iclepertin (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Apr 2019 Results evaluating the safety profile, tolerability, pharmacokinetics, and dose proportionality of BI 425809 healthy chinese and japanese subjects published in the Clinical Therapeutics
- 13 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 30 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.